SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Efficacy and safety of trilaciclib to prevent chemotherapy-induced myelosuppression in advanced solid tumors: a systematic review and meta-analysis.
Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrilaciclib is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor that has shown promise in mitigating chemotherapy-induced myelosuppression (CIM). This meta-analysis aims to provide a comprehensive and clinically relevant quantification of trilaciclib's effectiveness in reducing CIM and its potential impact on outcomes in adult patients with solid tumors.
methodsWe performed a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies evaluating trilaciclib administered along with chemotherapy in adult patients (≥ 18 years) with advanced or metastatic solid tumors. Databases searched included PubMed, Embase, the Cochrane Library, and major trial registries (ClinicalTrials.gov, EU Clinical Trials Register, ICTRP) up to May 21, 2025. Primary outcomes were incidence of grade 3/4 neutropenia, febrile neutropenia (FN), need for granulocyte-colony stimulating factors (G-CSF)/erythropoiesis-stimulating agents (ESA), and need for red blood cell/platelet transfusions. Efficacy endpoints included progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). Pooled odds ratios (OR) or hazard ratios (HR) were calculated using a random-effects model. Heterogeneity was assessed with the I
resultsTen studies with a total of 979 patients were included, with 586 receiving trilaciclib alongside chemotherapy and 393 receiving chemotherapy alone. Pooled analysis showed that trilaciclib decreased the incidence of grade 3/4 neutropenia by 79% (OR = 0.21; 95% CI: 0.08-0.52; I
conclusionTrilaciclib significantly reduced CIM and the need for hematopoietic support during chemotherapy. It also showed a positive impact on efficacy outcomes without compromising chemotherapy effectiveness or increasing toxicity. Overall, our findings support trilaciclib's evolving role as a promising adjunct to chemotherapy protocols in appropriately selected patients.
Indexed as
Identifiers
41642397What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.